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Cancer policymakers, researchers, and advocates have different priorities for 
cancer treatment research and may define ‘value’ of new treatments differently. 
Harmonizing the priorities and values of diverse stakeholders may be neither pos-
sible nor desirable. In November 2012, as part of its Patient Access to Cancer care 
Excellence (PACE) initiative, Lilly Oncology convened a Global Council of opinion 
leaders in cancer research, care, and policy to identify barriers to innovation in 
oncology research and develop strategies to improve cancer care. Participants 
concluded that the cancer policy field lacked tools to visualize these differences 
and to track progress in cancer treatments based on variable sets of values. 
Responding to this need, PACE developed the Continuous Innovation Indicators: 
novel, scientifically rigorous progress trackers designed to increase understand-
ing of continuous innovation in cancer treatments among different stakeholders. 
The Indicators quantify progress in cancer treatments by: 1) mining the literature 
to determine the strength of the evidence supporting each treatment; 2) weight-
ing the analysis according to the audience’s priorities and values; and 3) calcu-
lating Evidence Scores (E-Scores), which are measures of progress based on the 
strength of the evidence weighted by the assigned value. We introduce a flexible 
model to illustrate differing values, show how the values from the model can be 
used to weight the evidence from the scientific literature to obtain E-Scores, and 
demonstrate how assigning different values influences E-Scores. Differentiated 
analyses based on values provided by various stakeholders will help the cancer 
policy field to obtain accurate representations of the complex, stepwise progress 
against different cancers over time. We envision partnerships and collaborations 
to support educational efforts, identification and illustration of policy goals, and 
work in the field of health technology assessments. We will not make this tool 
available to individuals or organizations for the purpose of deriving treatment 
recommendations.
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It is widely accepted that, as well as developing new Clinical Outcome Assessments 
(COAs) for clinical trials, using existing COAs to evaluate treatment benefit from 
the patient perspective is often a more pragmatic, time- and cost-effective strat-
egy. However, the suitability of a COA (whether new or existing) is dependent on 
evidence of content and psychometric validity in a specific context and for spe-
cific concepts of interest. Determining which existing COA is most suitable based 
upon these criteria is particularly challenging when a large pool of instruments 
is available. For example, a recent MEDLINE search for COAs in head and neck 
cancer yielded more than 100 instruments. To shortlist from here, the logical next 
step is to review which COAs have been used (successfully and unsuccessfully) 
by sponsors in previous and ongoing trials. However, there is no clear guidance 
that explains how to identify relevant products or trials and what information to 
review to support measurement selection and ensure regulatory acceptance. Thus 
we outline an approach that is systematic, robust and pragmatic to support the 
selection of an existing COA for inclusion in upcoming studies. The Competitor 
Outcomes Landscape Analysis (COLA) methodology is a four-step approach: 1) 
identify relevant competitor drugs using a global clinical trial database, 2) review 
the Drugs@FDA database and the EMA’s European Public Assessment Reports to 
establish approval status and identify COAs included in labelling, 3) review FDA’s 
Drug Approval Packages to document regulatory decision-making and 4) identify 
COAs included in trial protocols for drugs in development. The COLA approach 
helps sponsors to select the most appropriate COA for studies in a specific popu-
lation and disease area. We believe this framework allows for more confidence, 
transparency and credibility in the decision-making process and as such COLA is 
a systematic approach to support an optimal COA strategy.
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Optimising the value of monitoring tests is currently under-researched. 
Conventionally, tests are repeated at fixed intervals using a fixed test cut-point 
value. Theory however suggests that diagnostic test performance changes with 
repeated use in any given population. We hypothesize that conventional practice 
may be sub-optimal. A simulation model is built to determine the test cut-point 
and retest interval which maximize population health. A simulated experiment is 
carried out on a hypothetical population of 10,000 patients who are being moni-
tored for disease progression or remission of some chronic disease for a period 
of 6months. a dichotomous test is applied on the population each month for the 
entire monitoring period. The patients are repeatedly stratified into diagnostic 
sub-populations (positive or negative) after each test, using a cut-point value 
between 0 and 1. The test performance and optimal cut-point in each sub-popu-
lation is measured after each repetition. Patients are then allowed only two tests 
within a monitoring period. We allow the retest interval and cut-point value to 
vary simultaneously across sub-populations. Population net health benefit (in 
QALYs) is estimated for all possible intervals and cut-points, and the optimal cut-
point and retest interval is determined. Preliminary results from our hypothetical 
simulation suggests that patients should be initially diagnosed using a cut-point 
of 0.25. Patients with a positive diagnosis should be re-tested after 4 months using 
a cut-point of 0.55, while those with a negative diagnosis should be re-tested after 
2 months using a cut-point of 0.20. The most efficient conventional strategy is 
associated with an expected health loss of 50 QALYs across the population com-
pared to the optimal strategy. Maximising the value of a monitoring test requires a 
dynamic test cut-off with respect to population characteristics based on previous 
test results, and the re-test interval.
dominancy is a key to answer, we aimed to formulate an analytical criterion which 
judges the extended dominancy of a new technology in comparison with the SOC 
and placebo. Methods: Assume the ICER of a new technology is evaluated with 
expected effectiveness Ex and cost Cx, compared to placebo or the SOC, respec-
tively, with a pair of effectiveness and cost: (Ep, Cp) and (Es, Cs), where Ep < Es < 
Ex and Cp < Cs < Cx. Then, regarding an ICER as the slope between two points on 
the cost-effectiveness plane, the concept of extended dominancy was materialized 
through a geometric approach so that the slope of the line connecting between a 
new technology and the SOC should be shallower than that between the SOC to 
placebo. Results: The analytical development resulted in the following criterion: 
if the expected cost Cx is smaller than the value of aEx + b, where a = (Cs - Cp) / (Es - 
Ep) and b = (CpEs - CsEp) / (Es - Ep), then the new technology can be judged as being 
extended dominant to the SOC. It implies the ICER of the new technology compared 
to the SOC must be smaller than that compared to placebo. If Cx is greater than 
aEx + b, the extended dominancy disappears with the ICER to the SOC greater than 
that to placebo. ConClusions: The criterion would be useful for decision makers 
to judge the extended dominancy and further to know the magnitude relationship 
between two ICERs of a new technology compared to the SOC or placebo.
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oBJeCtiVe: To present the concept of the expanded number needed to treat (NNT) as 
a potential decision aid for continuous outcome measures, to show how the expanded 
NNT can be derived from results of health economic analyses, to review some exam-
ples, and to discuss potential benefits and limitations. METHOD: The NNT, calcu-
lated as the inverse of the absolute risk reduction, provides clinicians and patients 
with intuitive risk-benefit information based on natural frequencies as opposed 
to reporting statistics in terms of probabilities, such as relative and absolute risks. 
However, one significant limitation of the NNT is that it only applies to binary out-
comes. Methods have been developed for estimating NNTs for continuous outcome 
measures, for example by dichotomizing outcomes according to whether a minimal 
clinically important difference is achieved. These methods may be appropriate for 
clinical decision making but may not be necessary for continuous outcomes, such 
as LYs and QALYs, when considered from the perspective of a health policy decision 
maker at the societal level. Accordingly, we propose the concept of the expanded 
NNT, calculated as the inverse of the difference in outcomes or, alternatively, as the 
incremental cost-effectiveness ratio divided by the incremental costs. The expanded 
NNT is a measure of clinical benefit, informing decision makers of how many peo-
ple would need to be treated with one intervention versus another to achieve one 
additional unit of outcome (eg, LY or QALY). We review some differences between the 
NNT and expanded NNT, provide some worked examples, and discuss the potential 
benefits and limitations of the expanded NNT. CONCLUSION: The expanded NNT may 
provide policy makers with a more intuitive metric to compare the clinical benefit 
of population level interventions involving LYs and QALYs and is consistent with 
standard methods of health economic decision making.
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Disease simulators model the evolution of biomarkers or clinical events character-
izing the disease in question over different time horizons, populations or treatment 
options. At the core of simulators are inter-connected equations that capture how 
patients’ characteristics impact changes in biomarkers and events over time. Many 
considerations go into the derivation and validation of such equations. Using exam-
ples from the development of an Alzheimer’s disease (AD) simulator, we call attention 
to a few specific issues and provide guidance on how to address these. The first issue 
concerns the parameterization of outcomes; for instance, predicting change from 
baseline versus previous visit, or determining whether a transformation is required. 
A practical consideration in choosing among formulations is the simplicity of the pat-
tern of change over time for each option, which can both enhance the fit and facilitate 
interpretation. Furthermore, one must consider how the effect of treatments on these 
markers is typically reported, so that these can be easily studied in the simulator. A 
more intricate issue lies in correctly capturing the inter-dependence of the various 
outcomes in the simulation without amplifying co-linearity between predictors. For 
instance, in AD, functionality depends on cognitive ability; thus, various measures 
of cognition can be helpful in predicting change in functionality over time. These 
measures of cognitive ability may be highly correlated, but have complimentary 
associations with functionality. High co-linearity can limit the generalizability of 
the equations beyond the source data and over long projection windows, and yield 
illogical predictions. The optimal formulation must balance the relative importance of 
correlated predictors with the relative gain in fit. Finally, we address validation, more 
specifically, the clinical plausibility of individual equation forms and results when 
equations are integrated together, and the propagation of errors as predictions from 
one equation are used to predict other outcomes.
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